Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Overview
Apyx Medical Corporation is an energy technology company distinguished by its innovative plasma‐based medical devices utilized in both the cosmetic and hospital surgical markets. The company develops, manufactures, and markets advanced energy solutions that provide surgeons with precise and controlled heat applications, addressing both tissue cutting and coagulation needs. Operating under a dual-segment framework, its services are divided into Advanced Energy and Original Equipment Manufacturing (OEM), each contributing uniquely to its overall market presence. Its technology portfolio, including the Renuvion and J-Plasma systems, leverages patented helium plasma technology and specialized waveforms, enabling high-performance surgical applications and reducing unintended tissue trauma.
Advanced Energy Solutions
The Advanced Energy segment of Apyx Medical Corporation centers on its core plasma-based technologies. These systems are designed to offer enhanced control during surgical and cosmetic procedures by delivering precise energy in the form of helium plasma. Surgeons in both cosmetic and hospital surgical environments benefit from these technologies through improved accuracy and reduced collateral tissue damage. The company has strategically engineered its products to support various applications, ranging from body contouring and soft tissue ablation to coagulation, positioning itself as a key player in the energy technology medical device industry. The integration of over 90 clinical documents demonstrates a consistent level of clinical validation and supports the efficacy and safety profiles of these advanced energy solutions.
OEM Manufacturing Capabilities
In addition to its Advanced Energy segment, Apyx Medical Corporation is also prominently involved in the Original Equipment Manufacturing (OEM) sector. By designing and producing electrosurgical generators and related accessories, the company not only markets its own devices but also partners with other leading medical device manufacturers. This dual approach enables Apyx to extend its technological expertise to a wider market, enhancing its revenue streams while fostering innovation across the medical device landscape. The OEM segment benefits from the company’s deep experience in developing unique waveform technologies and precision energy delivery, making it an indispensable partner in the creation of next-generation medical devices.
Technology and Innovation
The technological backbone of Apyx Medical Corporation lies in its pursuit of innovation within the energy technology sector. The company’s patented plasma-based systems, marketed under brands such as Renuvion and J-Plasma, are at the forefront of modern electrosurgical applications. These systems enable controlled energy delivery, allowing surgeons to work with enhanced precision and significantly reducing the risk of unintended tissue trauma. The controlled heat delivery mechanisms are particularly critical in cosmetic and reconstructive procedures, where precision is paramount. The company’s considerable investment in research and clinical studies underpins its commitment to technological excellence, providing a robust foundation for continuous improvements and product enhancements.
Market Position and Industry Impact
Apyx Medical Corporation occupies a distinct position within the broader energy technology and medical device sectors. With a reputation for developing innovative plasma-based surgical solutions, the company serves a diverse clientele including plastic surgeons, facial plastic surgeons, and cosmetic physicians. Its technologies are integral in procedures that demand high precision and minimal invasiveness. The advanced energy solutions not only address existing surgical challenges but also set new standards in terms of device performance and patient safety. This strategic positioning is further reinforced by the company’s OEM collaborations, which enable it to disseminate its expertise across various facets of the medical device industry. While navigating a competitive environment that includes both established and emerging players, Apyx distinguishes itself through its commitment to refining technological innovations and adhering to rigorous clinical standards.
Operational Excellence and Quality Assurance
Operational excellence is a core tenet of Apyx Medical Corporation’s business model. The company emphasizes rigorous quality control processes during the design, development, and manufacturing phases of its products. Such practices ensure that every device meets stringent safety and performance criteria, a crucial factor in the highly regulated medical device industry. Through continuous process improvements and quality management systems, the company maintains a robust operational framework that supports its long-term sustainability and reliability as a technology provider. This commitment to excellence enhances trust among healthcare professionals and institutional partners alike.
Clinical and Surgical Applications
The practical applications of Apyx Medical Corporation’s technologies span a wide range of clinical and surgical environments. In cosmetic surgery, the Renuvion system offers a transformative approach to body contouring by providing controlled energy delivery tailored for precision and minimal invasiveness. Similarly, the J-Plasma system is engineered to meet the rigorous demands of hospital surgical procedures, ensuring that surgeons can achieve effective tissue modification with enhanced safety. The integration of clinical evidence into its product development process further confirms the efficacy of these applications, thereby fortifying the company’s reputation in the clinical community. This dual-application strategy not only broadens the market reach but also underscores the versatility and adaptability of the company’s technological solutions.
Strategic Collaborations and Market Expansion
Apyx Medical Corporation’s strategic approach includes forging key partnerships within the medical device sector through OEM arrangements. These collaborations facilitate the integration of its advanced energy technologies into the broader ecosystem of medical devices, thereby driving market expansion. By leveraging the expertise of established industry partners, the company is able to refine its product offerings, gain new insights into market demands, and maintain a competitive edge. Such collaborations ensure that Apyx remains at the cutting edge of medical technology innovation, thereby continuously reinforcing its value proposition.
Expertise and Authoritativeness
The company’s extensive experience and technical expertise in the field of energy-based surgical solutions are evident in its comprehensive portfolio and the clinical validation of its products. With a heritage rooted in decades of research and innovation, Apyx Medical Corporation has developed a robust framework for understanding and addressing the complex challenges inherent in both cosmetic and surgical treatments. This depth of expertise is reflected in the strategic development and deployment of its technologies, which combine precision engineering with a clear understanding of clinical needs. The company’s ability to deliver solutions that optimize surgical outcomes while minimizing risks highlights its authoritative presence in the energy technology space.
Competitive Landscape and Differentiation
Within a competitive market populated by several established players, Apyx Medical Corporation differentiates itself through its unique blend of advanced energy technology and strategic OEM partnerships. Its focus on precision, safety, and controlled heat delivery distinguishes its product offerings from traditional electrosurgical instruments. The company’s approach to integrating clinical evidence with innovative technology ensures that its solutions are both effective and reliable. This differentiation is critical in an industry where technological nuances can significantly impact surgical outcomes and patient safety. By continually investing in research and maintaining rigorous quality standards, Apyx positions itself as a trusted provider of cutting-edge medical technologies.
Conclusion
In summary, Apyx Medical Corporation exemplifies the convergence of energy technology and advanced medical device manufacturing. Its dual-segment operation, spanning both advanced energy products and OEM manufacturing, enables the company to offer comprehensive solutions that address critical needs in cosmetic and surgical applications. Through its innovative plasma-based systems, the company delivers unmatched precision and safety, supported by an extensive body of clinical research and a commitment to operational excellence. As a respected contributor to the energy technology and medical device industries, Apyx continues to influence the standard of care in surgical procedures, making it a subject of ongoing interest for investors, healthcare professionals, and industry analysts alike.
Apyx Medical Corporation (NASDAQ:APYX) announced that its Renuvion neck laxity procedure will be featured on 'The Balancing Act' talk show on Lifetime on February 13, 2023, at 7:30 am ET/PT. The segment will showcase a minimally invasive neck procedure performed by Dr. Charles J. Galanis, highlighting its effectiveness in reducing sagging skin. Renuvion is the only FDA-cleared product for addressing neck and chin skin laxity, offering patients minimal downtime and cost-effectiveness. The segment will also re-run on February 21, 2023, with additional broadcasts throughout the year.
Apyx Medical Corporation (NASDAQ:APYX) has submitted a 510(k) premarket notification to the U.S. FDA for its Renuvion APR Handpiece, aiming to expand its use for coagulating subcutaneous soft tissues after liposuction. Supported by a clinical study and extensive evidence, the submission indicates that no new risks are associated with Renuvion when used post-liposuction. CEO Charlie Goodwin expressed optimism about receiving the FDA clearance, which may alleviate existing limitations outlined in the Medical Device Safety Communication.
Apyx Medical Corporation (NASDAQ: APYX) has launched the Apyx One Console, an advanced energy system now available to U.S. medical professionals. This multi-functional generator integrates Renuvion technology with monopolar and bipolar energy capabilities. Key features include adaptive touch screens, cloud connectivity, and a four-year warranty. Designed in collaboration with leading physicians, the Apyx One Console aims to enhance user experience and provides an upgrade option for existing customers. This product reinforces Apyx's commitment to innovation in the cosmetic surgery market.
Apyx Medical Corporation (NASDAQ:APYX) reported preliminary revenue results for Q4 and full year 2022, revealing a total revenue range of $12.1 to $12.5 million for Q4, a decline of 28% to 26% year-over-year. For the full year, revenue ranged from $44.0 to $44.4 million, declining by 9% to 8% year-over-year. The Advanced Energy segment showed significant declines of 33% to 30% in Q4 and 15% to 14% for the full year, while OEM revenue grew 12% in Q4 and 37% for the year. Despite challenges, the company plans for over 35% growth in 2023 driven by regulatory objectives.
Apyx Medical Corporation (NASDAQ: APYX) announces the launch of its inaugural direct-to-consumer campaign, #ThisIsMe, aimed at promoting its Renuvion technology for minimally invasive procedures. The campaign features national digital advertising and social media initiatives targeting consumers seeking aesthetic improvements. This campaign follows recent FDA clearances for Renuvion, specifically for treating loose skin on the chin and neck. The marketing efforts are designed to enhance brand awareness and highlight the technology's unique benefits, positioning Renuvion as a leader in cosmetic procedures.
Apyx Medical Corporation (NASDAQ:APYX) announced its participation in the Piper Sandler 34th Annual Healthcare Conference on November 30 at 11:00 a.m. ET, held at the Lotte New York Palace. Management will engage in a fireside chat, accessible via a live audio webcast on the Company's investor relations website.
Apyx Medical specializes in advanced energy technologies, notably its Helium Plasma Technology branded as Renuvion® for cosmetic and J-Plasma® for surgical markets, offering innovative solutions for tissue management.
Apyx Medical Corporation (NASDAQ: APYX) reported third-quarter 2022 results, revealing total revenue of $9.1 million, down 23% year-over-year. Advanced Energy revenue fell 31% to $7.1 million, while OEM revenue rose 34% to $2.0 million. The company recorded a net loss of $5.8 million, worsening from $4.2 million in Q3 2021. Due to ongoing disruptions from an FDA Safety Communication, Apyx revised its 2022 revenue guidance to a range of $44.8 million to $47.9 million, reflecting a potential decline of 8% to 1%. The management emphasized efforts to engage customers and secure new regulatory clearances.
Apyx Medical Corporation (NASDAQ:APYX) will release its third quarter financial results for fiscal year 2022 before the market opens on November 10th. A conference call, scheduled for 8:00 a.m. ET on the same day, will discuss the quarterly results and include a question and answer session. Interested participants can join via phone or listen to a live webcast through the company’s Investor Relations webpage. A replay of the call will be available for two weeks post-event.
Apyx Medical Corporation (NASDAQ: APYX) announced a new surgeon testimonial video featuring its Renuvion Helium Plasma Technology. Leading plastic surgeons, including Dr. Paul Nassif, attest to the device's effectiveness in achieving superior cosmetic results. Renuvion is FDA-cleared for improving lax skin on the neck and for specific dermatological procedures. Hundreds of physicians in the U.S. utilize this innovative technology in their practices, highlighting its safety and efficacy.
Apyx Medical Corporation (NASDAQ:APYX) has announced its participation in the Lake Street Best Ideas Growth Conference on September 14th at The Yale Club, New York, NY. Management will engage in one-on-one meetings, but there will not be a formal presentation. The company specializes in advanced energy technology, offering innovative helium plasma products such as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgeries. These technologies provide controlled heating for optimal surgical results.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
What is Apyx Medical Corporation's core business?
How does Apyx generate revenue?
What are the main technologies used by Apyx Medical Corporation?
Who are the primary customers of Apyx Medical Corporation?
How does the company ensure the safety and efficacy of its products?
What differentiates Apyx Medical Corporation from its competitors?
In what ways does the company support clinical applications?
What role do OEM partnerships play for Apyx Medical Corporation?
